Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
0.3800
+0.0174 (4.80%)
At close: Jun 6, 2025, 4:00 PM
0.3581
-0.0219 (-5.76%)
After-hours: Jun 6, 2025, 6:53 PM EDT
Equillium Revenue
Equillium had revenue of $30.41M in the twelve months ending March 31, 2025, down -19.76% year-over-year. In the year 2024, Equillium had annual revenue of $41.10M with 13.89% growth.
Revenue (ttm)
$30.41M
Revenue Growth
-19.76%
P/S Ratio
0.44
Revenue / Employee
$868,743
Employees
35
Market Cap
13.57M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
EQ News
- 4 weeks ago - Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists - Business Wire
- 5 weeks ago - Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 - Business Wire
- 6 weeks ago - Equillium Announces Feedback from the U.S. Food and Drug Administration - Business Wire
- 2 months ago - Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients - Benzinga
- 2 months ago - Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - Business Wire
- 2 months ago - Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Business Wire
- 4 months ago - Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - Business Wire
- 7 months ago - Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates - Business Wire